Diurnal Nears Market With Novel Adrenal Insufficiency Products
This article was originally published in Scrip
Two potential orphan drugs developed by the UK's newly public endocrinology speciality company, Diurnal Group, are in Phase III clinical trials, and the first of these, Infacort (immediate-release hydrocortisone) for pediatric patients with insufficient levels of the chemically-related essential hormone cortisol, could be approved in its first markets within 18 months, by the end of 2017.
You may also be interested in...
Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.
Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.